The global biopharmaceutical CMO and CRO market size was USD 36.21 billion in 2023, calculated at USD 38.56 billion in 2024 and is projected to surpass around USD 72.39 billion by 2034, expanding at a CAGR of 6.5% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Source Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Biopharmaceutical CMO and CRO Market, by Product Type, 2024-2034
7.1.1. Biologics
7.1.1.1. Market Revenue and Forecast (2021-2034)
7.1.2. Biosimilars
7.1.2.1. Market Revenue and Forecast (2021-2034)
8.1. Biopharmaceutical CMO and CRO Market, by Service, 2024-2034
8.1.1. Contract Manufacturing
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Contract Research
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Biopharmaceutical CMO and CRO Market, by Source, 2024-2034
9.1.1. Mammalian
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Non-Mammalian
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2021-2034)
10.1.2. Market Revenue and Forecast, by Service (2021-2034)
10.1.3. Market Revenue and Forecast, by Source (2021-2034)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Service (2021-2034)
10.1.4.3. Market Revenue and Forecast, by Source (2021-2034)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product (2021-2034)
10.1.5.2. Market Revenue and Forecast, by Service (2021-2034)
10.1.5.3. Market Revenue and Forecast, by Source (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2021-2034)
10.2.2. Market Revenue and Forecast, by Service (2021-2034)
10.2.3. Market Revenue and Forecast, by Source (2021-2034)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Service (2021-2034)
10.2.4.3. Market Revenue and Forecast, by Source (2021-2034)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Service (2021-2034)
10.2.5.3. Market Revenue and Forecast, by Source (2021-2034)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Service (2021-2034)
10.2.6.3. Market Revenue and Forecast, by Source (2021-2034)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product (2021-2034)
10.2.7.2. Market Revenue and Forecast, by Service (2021-2034)
10.2.7.3. Market Revenue and Forecast, by Source (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2021-2034)
10.3.2. Market Revenue and Forecast, by Service (2021-2034)
10.3.3. Market Revenue and Forecast, by Source (2021-2034)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Service (2021-2034)
10.3.4.3. Market Revenue and Forecast, by Source (2021-2034)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Service (2021-2034)
10.3.5.3. Market Revenue and Forecast, by Source (2021-2034)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Service (2021-2034)
10.3.6.3. Market Revenue and Forecast, by Source (2021-2034)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product (2021-2034)
10.3.7.2. Market Revenue and Forecast, by Service (2021-2034)
10.3.7.3. Market Revenue and Forecast, by Source (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2021-2034)
10.4.2. Market Revenue and Forecast, by Service (2021-2034)
10.4.3. Market Revenue and Forecast, by Source (2021-2034)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Service (2021-2034)
10.4.4.3. Market Revenue and Forecast, by Source (2021-2034)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Service (2021-2034)
10.4.5.3. Market Revenue and Forecast, by Source (2021-2034)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Service (2021-2034)
10.4.6.3. Market Revenue and Forecast, by Source (2021-2034)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product (2021-2034)
10.4.7.2. Market Revenue and Forecast, by Service (2021-2034)
10.4.7.3. Market Revenue and Forecast, by Source (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2021-2034)
10.5.2. Market Revenue and Forecast, by Service (2021-2034)
10.5.3. Market Revenue and Forecast, by Source (2021-2034)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Service (2021-2034)
10.5.4.3. Market Revenue and Forecast, by Source (2021-2034)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product (2021-2034)
10.5.5.2. Market Revenue and Forecast, by Service (2021-2034)
10.5.5.3. Market Revenue and Forecast, by Source (2021-2034)
11.1. Lonza
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. JRS Pharma
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Samsung Biologics
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. CMC Biologics
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. TOYOBO Co. Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. RentschlerBiotechnologie
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. FUJIFILM Diosynth Biotechnologies
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. WuXi Biologics
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Patheon
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. BoehringerIngelheim
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. PRA Health Sciences
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. LabCorp
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample